According to the report published by the Market Research Store, global demand for the leukapheresis market was estimated at approximately USD 94.7 Million in 2020 and is expected to generate revenue of around USD 580.1 Million by the end of 2026, growing at a CAGR of around 38.6% between 2021 and 2026.
Leukapheresis is a type of specifically modified apheresis procedure intended to take away leukocytes and return the residual cells such as the red blood cells, platelets, and granulocytes to the donor. In addition, the leukopaks (LPs) are leukapheresis samples taken from healthy peripheral blood. Leukapheresis is alike to apheresis where the red blood cells or platelets are extracted from blood, and the residual blood is sent to the body’s blood circulation. The separation of white blood cells from the sample of blood, which is occupied with the immune system of the body, is completed with a medical process, described as leukapheresis. The body’s high white blood cells could result in chronic blood cancers such as chronic lymphocytic leukemia (CLL), and hence leukapheresis is significant to be executed.
| REPORT SNAPSHOT & REPORTING DATA TIMEFRAME | |
|---|---|
| Parameter | Details |
| Historical Date ( Actual Data) | 2016 - 2020 |
| Base Year Data | 2020 |
| Current Year Data | 2021 |
| Projected Data | 2021 - 2026 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | product type, application, region |
| Regional scope | North America; Europe; Asia Pacific; Central & South America; Middle East & Africa |
| Country Scope | U.S.; Canada; Mexico; Germany; France; U.K.; China; Japan; South Korea; Singapore; Malaysia; Brazil; Saudi Arabia |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Significant factors fuelling the growth of the global leukapheresis market are the growing occurrence and prevalence of leukemia and the increasing demand for leukopaks for research applications.
However, the severe donor recruitment criteria, the high expenditure of cellular therapies and therapeutic leukapheresis, and the long procedural time for leukapheresis are some aspects that might hamper the market growth in the global leukapheresis to a certain level. Additionally, trained and skillful physicians or nurses are also needed for efficient treatment and the collection or removal of white blood cells using apheresis. This factor makes leukapheresis a costly device for temporary use. Conversely, the applications of therapeutic leukapheresis in pediatric patient treatment are becoming a part of the center for stakeholders in this sector. This will present lucrative opportunities during the forecast period.
Furthermore, the Covid-19 pandemic has formed a positive impact on the leukapheresis industry. The enduring clinical trials for making COVID-19 vaccines can influence positively the leukapheresis products industry, as the study of white blood cells is essential in supporting vaccine growth.
The global leukapheresis market has been categorized into product type, application, and end-user. On the basis of the type of product, the global market has been segmented into leukapheresis disposables and leukapheresis devices. Based on the application, the global market has been divided into research applications and therapeutic applications. In terms of the end-user industry, the global leukapheresis market has been separated into blood component providers and blood centers, pharmaceutical and biotechnology companies, academic and research institutes, and hospital and transfusion centers.
On the basis of geography, the global leukapheresis market is classified into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is expected to witness a major growth rate in the global leukapheresis market over the estimated period. The key factors responsible for the market growth in the region of North America are the growing occurrence of blood cancer and the occurrence of the huge number of foremost biotechnology companies in the region. The Asia-Pacific market is expected to go up at the highest growth rate in the global leukapheresis market in the upcoming years owing to the promising markets in the region that becomes major growth hotspots in the industry because of the rising prevalence of leukemia, the mounting elderly population, the development in healthcare infrastructure, the escalating public and private investments for the advancement of CAR-T therapy, and the growing amount of clinical trials in China.
Major market players operating in the global leukapheresis market include Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo BCT Inc., Miltenyi Biotec, Macopharma SA, Guangzhou Daji Medical Science and Technology Co. Ltd., PuriBlood Medical Co. Ltd., MEDICA S.p.A, and Beijing ZKSK Technology Co. Ltd.
Significant factors fuelling the growth of the global leukapheresis market are the growing occurrence and prevalence of leukemia and the increasing demand for leukopaks for research applications.
Global demand for the leukapheresis market was estimated at approximately USD 94.7 Million in 2020 and is expected to generate revenue of around USD 580.1 Million by the end of 2026, growing at a CAGR of around 38.6% between 2021 and 2026.
The North American region is expected to witness a major growth rate in the global leukapheresis market over the estimated period. The key factors responsible for the market growth in the region of North America are the growing occurrence of blood cancer and the occurrence of the huge number of foremost biotechnology companies in the region.
Major market players operating in the global leukapheresis market include Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo BCT Inc., Miltenyi Biotec, Macopharma SA, Guangzhou Daji Medical Science and Technology Co. Ltd., PuriBlood Medical Co. Ltd., MEDICA S.p.A, and Beijing ZKSK Technology Co. Ltd.
Leukapheresis
Leukapheresis
×